You are here: Skip Navigation LinksLeipzig University Cancer Center (UCCL)

​​Center for Personalized Medicine in Oncology – ZPM-O Leipzig

​​​​​​Center for PersonaliZed Medicine in oncology – ZPM-o Leipzig

Contact:

​Tel. +49 (0) 341 9721243
Fax +49 (0) 341 9728218

Further information can be found in our flyer and the ZPM-O contact card​.​

​​​​

Center for Personalized Medicine – Oncology

Evaluation of Molecular Therapy Options

A key focus of the Center for Personalized Medicine – Oncology (ZPM-O) is research and improvement of molecular diagnostics to provide all patients in Central Germany with the best possible care. By using state-of-the-art diagnostic methods and technologies, we perform comprehensive molecular analyses to gain insights into the underlying causes of cancer as well as mechanisms of treatment response and resistance.

The Center for Personalized Medicine is embedded within the structures of the University Cancer Center Leipzig (UCCL) under the leadership of Prof. Dr. Florian Lordick.

A central component of the Center is the integration of the well-established Molecular Tumor Board (MTB), which has been offered at the University Hospital Leipzig (UKL) within the UCCL since October 2019. In this interdisciplinary conference, experts from various medical specialties come together to discuss complex or therapeutically challenging cases and jointly develop tailored, targeted treatment strategies.​

Eröffnung ZPM.png

Press release on the opening of the Center for Personalized Medicine – Oncology (March 18, 2024)
Press release on the opportunities of precision oncology (January 30, 2025)

Partnerships of the Center for Personalized Medicine – Oncology:

​Further information on genomic medicine can be found in the explanatory video provided by the genomDE initiative: YouTube. A corresponding playlist with the individual modules is available here​.​​​



Precision Oncology Clinic (Sprechstunde)

At the University Cancer Center Leipzig, a Precision Oncology Clinic (Sprechstunde für Präzisionsonkologie) is offered for the in-person consultation of patients.

Registration is carried out by the treating physicians with a referral. The clinic serves for consultation and/or initiation of a molecular analysis (for ASV patients). External patients should already bring a referral for molecular analysis.

The clinic is recommended for personal contact with patients prior to discussion in the Molecular Tumor Board.

Lead:      Prof. Dr. Ulrich Hacker, Medical Clinic II

Location: Universitäres Krebszentrum Leipzig
              Liebigstr. 22, 04103 Leipzig
              House 7

Contact:  Tel. +49 (0) 341 9721243
              Fax +49 (0) 341 9728218

              E-Mail: Molekulares-Tu​morboard@medizin.uni-leipzig.de​

Press release​ on the Precision Oncology Clinic of the Center for Personalized Medicine – Oncology (October 1, 2024)

Molecular tumour board (MTB)


The Molecular Tumor Board (MTB) is an interdisciplinary tumor conference in which medical and scientific specialists from various departments discuss complex cancer cases. The discussion is based on the results of molecular pathology diagnostics, taking current scientific evidence into account. Subsequently, a recommendation is made for a precisely tailored treatment concept, further diagnostic procedures, or participation in a clinical study. Molecular Tumor Boards play an increasingly important role in the implementation of precision oncology (1)(2).

The MTB is held within the Comprehensive Cancer Center Central Germany (CCCG)​ in cooperation with the University Tumor Center Jena (UTC Jena).

  • Schedule: every two weeks (odd calendar weeks), Wednesdays at 3:00 pm
  • Registration deadline: Thursday of the preceding week, 2:00 pm
  • Registration: by the treating physicians only​​
​​
Participants

  • Treating physician (respective organ center)
  • Oncology
  • Pathology and Molecular Pathology
  • ​Human Genetics
  • Molecular Biology
  • Bioinformatics
  • Phase I Clinical Trial Unit (ECTU)
  • ​Additional disciplines as needed (Surgery, Radiology)


References

1. Yates LR, Seoane J, Le Tourneau C, et al. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology. 2018;29:30–35.

2. Westphalen BC, Bokemeyer C, Büttner R, et al. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group “Molecular Diagnostics and Therapy”. European Journal of Cancer. 2020;135:1–7.​


Further Information for Patients

Information on personalized oncology, whether such an analysis may be appropriate for you, as well as details on the process of the Molecular Tumor Board and the Precision Oncology Clinic, can be found in our flyer.

Please discuss your options with your treating oncologist or specialist physician. If your case is considered suitable, they will take care of registration and initiating the a molecular analysis.

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Your treating physician will also offer you the Broad Consent of the Medical Informatics Initiative (MII) funded by the German Federal Ministry of Education and Research (BMBF). This consent allows patient data from routine care to be made available for research purposes whenever possible.
By consenting to the confidential use of your data, you make an invaluable contribution to the advancement of medical research.
An overview of all relevant information can be found here, as well as in the corresponding flyer ​(PDF) and the patient information video.

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Further helpful information and services for patients and relatives can be found here: For Patients and Relatives

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Information on Support Groups:   The SHG Network
                                                Events by and for patients​

Molecular Support Groups:

BRCA-Netzwerk e.V.

  • The BRCA Network offers extensive peer support and experience-based guidance covering nearly all aspects of hereditary cancer. In individual consultations or group settings, in person or online, you can ask questions, share your feelings, or simply listen to others who are in similar situations. No one understands what you are going through better than people who have faced similar challenges themselves.
  • The goal is to support you comprehensively so that you can make informed and self-determined decisions based on your individual situation.
Address:  BRCA-Netzwerk e.V., Thomas-Mann-Str. 40, 53111 Bonn
Email:      info​@brca-netzwerk.de 
Phone:     +49 228 33889-100

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Here you can find an overview of upcoming events as well as reviews of past events.

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------​


External Registration for the Molecular Tumor Board (MTB)

Logistics:​

  • Schedule: every two weeks (odd calendar weeks) on Wednesdays at 3:00 pm
  • Registration deadline: Thursday prior to the respective MTB meeting at 2:00 pm.(In exceptional cases, individual arrangements may be possible.)
  • Format: virtual meeting via a web based video conferencing platform (Participation of the treating physician from external institutions is possible.)
  • The MTB team sends invitations to all participants in advance.
  • The MTB is conducted within the Comprehensive Cancer Center Central Germany (CCCG) in cooperation with Jena University Hospital.
  • Patient cases are discussed in a pseudonymized manner.
  • The MTB recommendation will be provided no later than one week after the meeting.
  • Assignment of evidence levels for the respective recommendations in the MTB reports is based on the NCT criteria (1).

Registration Documents

Please send the documents via fax to: +49 (0) 341 9728218

  • ​Registration form
  • ​Patient information and consent for presentation in interdisciplinary conferences
  • Broad Consent of the Medical Informatics Initiative (MII) (patient information)
  • Signing the Broad Consent is not a prerequisite for discussion of the case in the MTB. The consent allows patient data from routine care to be made available for research purposes. Further information can be found here, as well as in the corresponding flyer ​(PDF) and the patient information video.​
  • Current medical report
  • Molecular pathology findings (if available)
  • Radiological findings (if available)
  • Protocol of the organ specific tumor board, including the written recommendation for presentation in the MTB.
​Please ensure that all registration documents are complete, as incomplete registrations may lead to delays.

Please also check out​ our data protection regulations.


Molecular Pathology Diagnostics

Please send the original referral (and tumor material if needed) to our pathology service provider:

MVZ Pathologie
Liebigstr. 26
04103 Leipzig

  • Request: Molecular pathology testing (TSO500) and discussion in the Molecular Tumor Board (MTB)
  • Please specify the pathology department and the material number under which tumor tissue can be requested.
  • Template referral form for molecular pathology diagnostics
  • We recommend that patients attend the Precision Oncology Clinic for consultation and personal evaluation.
  • For patients with private health insurance, a cost estimate can be provided. Further information can be found here​.

Patient Selection Criteria

  • Advanced tumor disease
  • Good general condition allowing further molecularly stratified experimental therapy
  • Standard treatment options have been exhausted and no further promising therapeutic approaches are available (Patients are usually presented during the last established line of therapy)
  • Or: unusual clinical course (“informative patient”), rare tumor entity, or exceptional molecular pathology profile
  • Recommendation for presentation in the MTB was issued by an organ specific tumor board (please include the corresponding protocol)
  • Patient consent for discussion in the MTB has been obtained
  • Molecular pathology diagnostic results are already available or have been requested via referral at the UKL MVZ Pathologie (request: TSO500) shortly.


References:

1. Horak P, Klink B, Heining C, et al. Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer. 2017;141:877–886.


Internal Registration for the Molecular Tumor Board (MTB)

  • The MTB presentation is carried out by a member of the primary treating medical team.
  • Registration should only take place once the availability of molecular diagnostic results is foreseeable.
  • The Standard Operating Procedure (SOP) for the Molecular Tumor Board and additional documents are available in the Roxtra system: Center for Personalized Medicine.

Registration for the Molecular Tumor Board (MTB)

Registration for the Molecular Tumor Board should be sent to
and must include the following information:
  • Patient data
  • Name of the referring physician
  • Information on whether a TSO500 panel has been initiated or whether molecular pathology results are already available for discussion
  • U number and storage location of the tumor material

Templates provided:


Referral to MVZ Pathology, University Hospital Leipzig
​Address:   MVZ Pathologie
               Liebigstr. 26
               04103 Leipzig

Request:
Molecular pathology testing (TSO500) and discussion in the Molecular Tumor Board (MTB)

  • For ASV patients, molecular pathology testing may also be initiated within the Precision Oncology Clinic.


Indication for Molecular Pathology Testing

  • Indication for molecular pathology testing confirmed in the organ-specific tumor board
  • Advanced tumor disease
  • Good general performance status
  • Either: Standard treatment options are expected to be exhausted and no further promising therapeutic options are available
    Or: Unusual clinical course and or molecular pathology profile, rare tumor entity
  • A written recommendation for presentation in the Molecular Tumor Board must be documented in the decision or minutes of the organ-specific tumor board.
  • Further details can be found in the SOP “Indication for Molecular Panel Diagnostics in Malignancies”

Requesting Tumor Material from External Institutions (if applicable)

  • If tumor material must be requested externally, please use the following wording:
  • “We ki​ndly request shipment of the tumor material with the number H06550-24 to the following address:
Universitätsklinikum Leipzig AöR
Prof. Dr. med. Bläker 
z.H. Frau Transchel
Institut für Pathologie
Liebigstraße 26, Haus G, 04103 Leipzig​

  • Please provide the specimen with the highest tumor cell content.”

Registration for the MTB Observational Study

  • For every initiation of TSO500 testing, the patient should be enrolled in the MTB observational study.
  • MTB Study
  • Provide the patient with a copy of the signed consent form
  • File the original consent form in the designated folder
  • Document the consent process in the medical record
  • Example documentation text:
  • “A detailed discussion was held with the patient regarding participation in the MTB observational study. The patient was informed about the content and procedures of the MTB observational study in accordance with the current protocol, version 1.0 dated November 20, 2023. The patient signed the consent form, version 1.0 dated November 20, 2023, and received a copy. All open questions were addressed and the planned next steps were discussed. The patient agrees with the proposed procedure within the framework of the study.”


Upcoming Events

Gastrointestinale Onkologie 2026 – Update und Bewertung für die Praxis


im Namen von Prof. Florian Lordick, laden wir Sie herzlich zum dritten Netzwerktreffen in der Mitte Deutschlands: „Gastrointestinale Onkologie 2026 – Update und Bewertung für die Praxis“. Über die Besprechung wichtiger, auch Praxis-verändernder Daten hinaus, werden wir besonders vom kooperativen Austausch zwischen den Universitäten Leipzig-Jena, Hannover-Göttingen, Halle und Magdeburg und ihren jeweiligen Netzwerken profitieren.
Der Termin nach dem „ASCO-GI“ garantiert, dass wir vieles ganz Neues besprechen können.
Ein guter Start in das GI Onkologie Jahr 2026 – lassen Sie es sich nicht entgehen!

🗓  Mittwoch, 11. Februar 2026
🕠  17:00 – 19:50 Uhr​
📍    Hotel Michaelis - "Alte Essig Manufaktur" Raum Erdgeschoss
         Paul-Gruner-Straße 44, 04107 Leipzig

🎓    ​Link zum Flyer mit Programm

Ansprechpartnerin für Rückfragen & Registrierung: anika.sorgatz@msd.de​ 
Bitte nennen Sie in der Anmeldungsmail Ihren vollständigen Namen/ Vornamen, und das Institut/ Praxis/ die Einrichtung.​


Liebigstraße 22, Haus 7
04103 Leipzig
Telefon:
0341 - 97 12560 (Sekretariat)
Ambulanz:
0341 - 97 17365
Fax:
0341 - 97 12569
Map
7nach oben